Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 4—April 2005
Perspective

Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases

Anthony S. Fauci*, Nancy A. Touchette*Comments to Author , and Gregory K. Folkers*
Author affiliations: *National Institutes of Health, Bethesda, Maryland, USA

Main Article

Figure 4

AIDS cases, AIDS deaths, and persons living with AIDS in the United States, 1981–2003. Over the past decade, the number of new AIDS cases and deaths due to AIDS has decreased, while the number of people living with the disease has increased, due in large part to improvements in diagnosis and treatment. Estimates adjusted for reporting delays. Source: CDC (8).

Figure 4. AIDS cases, AIDS deaths, and persons living with AIDS in the United States, 1981–2003. Over the past decade, the number of new AIDS cases and deaths due to AIDS has decreased, while the number of people living with the disease has increased, due in large part to improvements in diagnosis and treatment. Estimates adjusted for reporting delays. Source: CDC (8).

Main Article

References
  1. Morens  DM, Folkers  GK, Fauci  AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;430:242–9. DOIPubMedGoogle Scholar
  2. Fauci  AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001;32:675–85. DOIPubMedGoogle Scholar
  3. Institute of Medicine. Microbial threats to health: emergence, detection and response. Washington, DC: The Institute; 2003.
  4. Infectious Diseases Society of America. Bad bugs, no drugs as antibiotic discovery stagnates. A public health crisis brews. Washington, DC: The Society; 2004.
  5. Jernigan  DB, Raghunathan  PL, Bell  BP, Brechner  R, Bresnitz  EA, Butler  JC, Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019–28.PubMedGoogle Scholar
  6. World Health Organization. The world health report 2004–changing history. Geneva: The Organization; 2004.
  7. UNAIDS. 2004 report on the global AIDS epidemic: 4th global report. [cited 2005 Feb 16]. Available from http://www.unaids.org/bangkok2004/report.html
  8. Centers for Disease Control and Prevention. HIV/AIDS surveillance report 2003. Atlanta: The Centers; 2003.
  9. Fauci  AS. HIV and AIDS: 20 years of science. Nat Med. 2003;9:839–43. DOIPubMedGoogle Scholar
  10. Graham  BS, Mascola  JR. Lessons from failure—preparing for future HIV-1 vaccine efficacy trials. J Infect Dis. 2005;191:647–9. DOIPubMedGoogle Scholar
  11. Klausner  RD, Fauci  AS, Corey  L, Nabel  GJ, Gayle  H, Berkley  S, The need for a global HIV vaccine enterprise. Science. 2003;300:2036–9. DOIPubMedGoogle Scholar
  12. Gardner  MJ, Hall  N, Fung  E, White  O, Berriman  M, Hyman  RW, Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511. DOIPubMedGoogle Scholar
  13. Holt  R Subramanian GM, Halpern A, Sutton GG, Charlab R, Nusskern DR, et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science. 2002;298:129–49. DOIPubMedGoogle Scholar
  14. Sidhu  AB, Verdier-Pinard  D, Fidock  DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298:210–3. DOIPubMedGoogle Scholar
  15. Johnson  DJ, Ficock  DA, Mungthin  M, Lakshmanan  V, Sidhu  ABS, Bray  PG, Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell. 2004;15:867–77. DOIPubMedGoogle Scholar
  16. Fidock  DA, Rosenthal  PJ, Croft  SL, Brun  R, Nwaka  S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004;3:509–20. DOIPubMedGoogle Scholar
  17. Jacobs-Lorena  M. Interrupting malaria transmission by genetic manipulation of anopheline mosquitoes. J Vector Borne Dis. 2003;40:73–7.PubMedGoogle Scholar
  18. Alonso  PL, Sacarlal  J, Aponte  JJ, Leach  A, Macete  E, Milman  J, Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet. 2004;364:1411–20. DOIPubMedGoogle Scholar
  19. World Health Organization. Portfolio of malaria vaccines currently in development, October, 2004. [cited 2005 Feb 16]. Available from http://www.who.int/vaccine_research/documents/en/malaria_table.pdf
  20. Reed  SG, Alderson  MR, Dalemans  W, Lobet  Y, Skeiky  YAW. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb). 2003;83:213–9. DOIPubMedGoogle Scholar
  21. Butcher  PD. Microarrays for Mycobacterium tuberculosis. Tuberculosis (Edinb). 2004;84:131–7. DOIPubMedGoogle Scholar
  22. Goguet de la Salmoniere  YO, Kim  CC, Tsolaki  AG, Pym  AS, Siegrist  MS, Small  PM. High-throughput method for detecting genomic-deletion polymorphisms. J Clin Microbiol. 2004;42:2913–8. DOIPubMedGoogle Scholar
  23. Skeiky  YA, Alderson  MR, Ovendale  PJ, Guderian  JA, Brandt  L, Dillon  DC, Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004;172:7618–28.PubMedGoogle Scholar
  24. Horwitz  MA, Harth  G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 2003;71:1672–9. DOIPubMedGoogle Scholar
  25. National Institute of Allergy and Infectious Diseases. Tuberculosis: ancient enemy, present threat. [cited 2005 Feb 16]. Available from http://www2.niaid.nih.gov/newsroom/focuson/tb02/tb.htm
  26. Centers for Disease Control and Prevention. Influenza Web page. Available from http://www.cdc.gov/flu/
  27. World Health Organization. Influenza Web page. [cited 2005 Feb 16]. Available from http://www.who.int/topics/influenza/en/
  28. National Institute of Allergy and Infectious Diseases. Press releases, May 27, 2004 and August 17, 2004. [cited 2005 Feb 16]. Available from http://www2.niaid.nih.gov/Newsroom/Releases/news.htm?year=2004
  29. Webby  RJ, Perez  DR, Coleman  JS, Guan  Y, Knight  JH, Govorkova  EA, Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet. 2004;363:1099–103. DOIPubMedGoogle Scholar
  30. Hatta  M, Gao  P, Halfmann  P, Kawaoka  Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293:1840–2. DOIPubMedGoogle Scholar
  31. Kobasa  D, Takada  A, Shinya  K, Hatta  M, Halfmann  P, Theriault  S, Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004;431:703–7. DOIPubMedGoogle Scholar
  32. Maassab  HF, Francis  T Jr, Davenport  FM, Hennessy  AV, Minuse  E, Anderson  G. Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull World Health Organ. 1969;41:589–94.PubMedGoogle Scholar
  33. Harper  SA, Fukuda  K, Cox  NJ. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003;52(RR-13):1–8.PubMedGoogle Scholar
  34. Komar  N. West Nile virus: epidemiology and ecology in North America. Adv Virus Res. 2003;61:185–234. DOIPubMedGoogle Scholar
  35. Hall  RA, Khromykh  AA. West Nile virus vaccines. Expert Opin Biol Ther. 2004;4:1295–305. DOIPubMedGoogle Scholar
  36. Shimoni  Z, Niven  MJ, Pitlick  S, Bulvik  S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis. 2001;7:759. DOIPubMedGoogle Scholar
  37. Borovsky  D. Trypsin-modulating oostatic factor: a potential new larvicide for mosquito control. J Exp Biol. 2003;206:3869–75. DOIPubMedGoogle Scholar
  38. National Institute of Allergy and Infectious Diseases. NIAID research on severe acute respiratory syndrome (SARS). [cited 2005 Feb 16]. Available from http://www.niaid.nih.gov/factsheets/sars.htm
  39. Yang  Z, Kong  WP, Huang  Y, Roberts  A, Murphy  BR, Subbarao  K, A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428:561–4. DOIPubMedGoogle Scholar
  40. Bisht  H, Roberts  A, Vogel  L, Bukreyev  A, Collins  PL, Murphy  BR, Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A. 2004;101:6641–6. DOIPubMedGoogle Scholar
  41. Bukreyev  A, Lamirande  EW, Buchholz  UJ, Vogel  LN, Elkins  WR, St Claire  M, Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363:2122–7. DOIPubMedGoogle Scholar
  42. Subbarao  K, McAuliffe  J, Vogel  L, Fahle  G, Fischer  S, Tatti  K, Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004;78:3572–7. DOIPubMedGoogle Scholar
  43. Traggiai  E, Becker  S, Subbarao  K, Kolesnikova  L, Uematsu  Y, Gismondo  MR, An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–5. DOIPubMedGoogle Scholar
  44. National Institute of Allergy and Infectious Diseases. NIAID biodefense research. [cited 2005 Feb 16]. Available from http://www2.niaid.nih.gov/biodefense/
  45. National Center for Biotechnology Information. Entrez Genome. [cited 2005 Feb 16]. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Genome
  46. Earl  PL Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428:182–5. DOIPubMedGoogle Scholar
  47. Wyatt  LS, Earl  PL, Eller  LA, Moss  B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A. 2004;101:4590–5. DOIPubMedGoogle Scholar
  48. Sullivan  NJ, Geisbert  TW, Geisbert  JB, Xu  L, Yang  ZL, Roederer  M, Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681–4. DOIPubMedGoogle Scholar
  49. Titball  RW, Williamson  ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther. 2004;4:965–73. DOIPubMedGoogle Scholar

Main Article

Page created: May 23, 2011
Page updated: May 23, 2011
Page reviewed: May 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external